SAN DIEGO - Kintara Therapeutics, Inc. (NASDAQ: KTRA), a biopharmaceutical company, has announced that its Board of Directors has approved a reverse stock split at a ratio of 1-for-35. This corporate action precedes the expected trading of Kintara's common stock under the new name TuHURA Biosciences, Inc. and ticker symbol "HURA" on the Nasdaq Capital Market starting October 18, 2024, following a planned merger with TuHURA Biosciences, Inc. The previous announcement inaccurately stated that trading would commence on October 17, 2024.
The reverse stock split, ratified by stockholders on October 4, 2024, will consolidate every thirty-five shares of Kintara's existing common stock into one share. Post-split, the anticipated reduction in outstanding shares will be from approximately 55.6 million to about 1.6 million, with the par value per share remaining at $0.001. The authorized number of shares will not change. The adjustment is intended to be equitable for all stockholders; however, no fractional shares will be issued. Instead, stockholders will receive an additional fraction of a share as necessary to round up to a full share.
The reverse stock split will also proportionately adjust the terms of Kintara's outstanding warrants and stock options, as well as the shares under the company's equity incentive plans. After the merger's completion, the combined company's total outstanding common stock is expected to reach approximately 42.0 million shares.
Equinity Trust Company, LLC will serve as the exchange and transfer agent for the reverse stock split process. Shareholders with shares in book-entry form or held through brokerage accounts do not need to take any action. Beneficial holders with questions about the procedure should contact their bank, broker, or custodian.
The information is based on a press release statement from Kintara Therapeutics.
In other recent news, Kintara Therapeutics has received authorization for a 1-for-35 reverse stock split, as it prepares to rebrand as TuHURA Biosciences. This move follows a stockholder vote and precedes the anticipated merger between the two companies. The merger will result in TuHURA becoming a wholly-owned subsidiary of Kintara.
In the run-up to the merger, Kintara has amended the issuance of Contingent Value Rights (CVRs) to its stockholders, which will be distributed immediately before the reverse stock split. Kintara's shareholders have also approved several proposals, including the issuance of common stock related to the merger agreement and the reverse stock split, although the proposal to increase the authorized shares of Kintara’s common stock did not pass.
Kintara has made significant strides in cancer treatment development, notably its REM-001 therapy for cutaneous metastatic breast cancer, which has shown promising results. Similarly, TuHURA Biosciences is making progress with its Phase 3 immuno-oncology pipeline, including its leading cancer vaccine candidate, IFx-2.0.
Finally, at Kintara's recent Annual Meeting of Stockholders, four directors were elected, the compensation of the company's executive officers was approved, and Marcum LLP was appointed as Kintara's independent registered public accounting firm for the fiscal year ending June 30, 2024.
InvestingPro Insights
As Kintara Therapeutics (NASDAQ: KTRA) prepares for its reverse stock split and merger with TuHURA Biosciences, investors should consider some key financial metrics and insights from InvestingPro.
According to InvestingPro data, Kintara's market capitalization stands at $11.51 million, reflecting its current small-cap status. This valuation aligns with the company's decision to implement a reverse stock split, which is often used by smaller companies to boost their share price and maintain listing requirements.
InvestingPro Tips highlight that Kintara holds more cash than debt on its balance sheet, which could provide some financial flexibility during the transition period. However, the company is also quickly burning through cash, a common characteristic of biopharmaceutical firms in development stages.
Interestingly, Kintara has seen a significant return over the last week, with a 22.11% price increase, and a strong 34.88% return over the last month. This recent positive momentum might be related to the announced merger and corporate restructuring.
It's worth noting that analysts do not anticipate the company to be profitable this year, which is not unusual for early-stage biopharmaceutical companies. This aligns with the InvestingPro data showing an adjusted operating income of -$8.45 million for the last twelve months.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Kintara Therapeutics, providing a deeper understanding of the company's financial health and market position as it undergoes this significant transformation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.